Sarfez Pharmaceuticals, Inc. | Inventing Inventions



Leaders in clinical and translational research

SAB... Leaders in clinical and translational research
Print this page Decrease text size Increase text size

Scientific Advisory Board

Bertram Pitt, M.D.
Christopher Wilcox, Ph.D., M.D.
Domenic Sica, Ph.D., M.D.
Guru Betageri, Ph.D.
Peter Feig, M.D.



Bertram Pitt, M.D.

Dr. Pitt is a Professor of Internal Medicine Emeritus, University of Michigan School of Medicine and was the Director, Division of Cardiology for 15 years.

Dr. Pitt's research encompasses several areas of cardiovascular disease, with special emphasis on ischemic heart disease and heart failure.  Dr. Pitt is author of over 500 papers and book chapters and is on the Editorial Board on a number of journals of cardiovascular diseases.  Among professional organizations, he was Chairman, Council on Circulation of the American Heart Association, President of the Michigan Chapter of American College of Cardiology, Chairman, Young Investigator's Award Committee of the American College of Cardiology, and Chairman of the Research Committee of the ACC.  He has received the James B. Herrick Award from the American Heart Association and the Lifetime Achievement Award from the Heart Failure Society of America.

Dr. Pitt has been principal or co-principal investigator of several clinical trials, such as the Digitalis-Captopril Trial (300 patients), Studies of Left Ventricular Dysfunction (SOLVD - 6,700 patients), Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC Study - 600 patients), QUIET Study (1,750 patients), Prevent Trial (600 patients), Reflect II Trial (300 patients), RALES trial (3,200 patients), Ephesus (6,400 patients), ELITE II (3,000 patients), EMPHASIS-HF ( 2737 patients ).  He is currently chairman of the Steering Committee of the NHLBI TOPCAT trial (3445 patients).

Dr. Pitt received his postdoctoral training at Beth Israel Hospital Boston and the Johns Hopkins Hospital University, and received his M.D. from the University of Basel, Switzerland.

 Back to top


Christopher Wilcox, Ph.D., M.D.

Dr. Wilcox is Chief of the Division of Nephrology and Hypertension, and Director of the Hypertension, Kidney and Vascular Research Center at the Georgetown University Medical Center.

Dr. Wilcox has extensive experience in both non-clinical and clinical research in hypertension and kidney diseases.  He is the author of more than 500 original scientific articles and two books on nephrology and hypertension.  He has received numerous grants from federal and non-federal sources and chairs four NIH peer review groups. He has delivered eight name lectures at various universities in the United States and awarded the Lifetime Achievement Award by the American Heart Association (AHA).  He has delivered the Dahl lecture at the AHA and the Frank Starling Lecture to the American Physiology Society.  He has been elected a Fellow of the Royal Society of Medicine and a Fellow of the Royal College of Physicians in the UK and a Master of the American College of Physicians and a Fellow of the American Association of Professors.

Dr. Wilcox received certifications in Nephrology and Internal Medicine, an Internship, Fellowship, Residency and a PhD from London University, UK, with a specialization in Renal Physiology.  His medical degree is from Oxford University, UK, with a Medicine/Surgery specialization.

 Back to top


Domenic Sica, Ph.D., M.D.

Dr. Sica is a Professor of Medicine and Pharmacology at the Medical College of Virginia of Virginia Commonwealth University.  A strong area of interest for him is on issues of drug elimination in renal disease as well as the mechanistic understanding of diuretics and their neurohormonal effects.  Dr. Sica's current areas of research and special interest are in the areas of drug pharmacokinetics/pharmacodynamics, pharmacotherapy of hypertension, and deterrents of renal failure progression.  He has received numerous research grants, has published more than 400 articles and edited several books in the areas of hypertension, cardiovascular pharmacotherapeutics, and lipidology.

Dr. Sica received his M.D. from Virginia Commonwealth University and Fellowship in Nephrology from the University of Texas Health Science Center in San Antonio.  He currently is President-Elect of the American Society of Hypertension.

 Back to top


Guru Betageri, Ph.D.

Dr. Betageri is Professor of Pharmaceutical Sciences and Associate Dean of the Graduate College of Biomedical Sciences, Western University of Health Sciences, California.

Dr. Betageri is one of the leading experts in the area of "Liposome Drug Delivery" systems and has received several grants from federal agencies and private foundations.  His research has been translated into several drug products on the market.  He has published more than 70 original research articles and presented more than 100 papers at national and international conferences.  He is a reviewer for more than 12 pharmaceutical journals and member of editorial boards.  He has authored the book entitled "Liposome Drug Delivery" and co-authored several book chapters.  He has several US and international patents to his credit.

Dr. Betageri received Bachelors of Pharmacy degree from Karnatak University, a Masters of Pharmacy from Bangalore University and a Ph.D. degree in Pharmaceutical Sciences from the University of Alberta, Edmonton, Canada.

 Back to top


Peter Feig, M.D.

Dr. Feig has spent more than 20 years in various executive roles in the pharmaceutical industry, most recently at Merck Research Laboratories, with responsibility for cardiovascular programs worldwide.  As an executive in the pharmaceutical industry, Dr. Feig has taken several products from Phase I through marketing approval and has had key roles in worldwide in- and out-licensing and development of marketing strategies.  Since 2008, Peter has been a faculty member of the Columbia University College of Physicians and Surgeons, an outpatient physician at Columbia Presbyterian Hospital and a teaching faculty member in the Nephrology Division.  Peter trained as a Clinical Fellow (Nephrology) at Beth Israel Hospital, Boston, MA, and as a Research Fellow at Harvard Medical School, Boston, MA.  His therapeutic areas of expertise are cardiovascular and metabolic diseases.  He has been the recipient of many public and private research grants and has authored or co-authored more than 90 original articles, reviews, book chapters and abstracts.

Peter, a board certified internist and nephrologist, has an M.D. from University of Sao Paulo School of Medicine, Sao Paulo, Brazil.

 Back to top





Copyright © 2016. All rights reserved. Sarfez Pharmaceuticals, Inc.